These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 38630755)

  • 1. Spatially Preserved Multi-Region Transcriptomic Subtyping and Biomarkers of Chemoimmunotherapy Outcome in Extensive-Stage Small Cell Lung Cancer.
    Peressini M; Garcia-Campelo R; Massuti B; Martí C; Cobo M; Gutiérrez V; Dómine M; Fuentes J; Majem M; de Castro J; Córdoba JF; Diz MP; Isla D; Esteban E; Carcereny E; Vila L; Moreno-Vega A; Ros S; Moreno A; García FJ; Huidobro G; Aguado C; Cebey-López V; Valdivia J; Palmero R; Lianes P; López-Brea M; Vidal OJ; Provencio M; Arriola E; Baena J; Herrera M; Bote H; Molero M; Adradas V; Ponce-Aix S; Nuñez-Buiza A; Ucero Á; Hernandez S; Lopez-Rios F; Conde E; Paz-Ares L; Zugazagoitia J
    Clin Cancer Res; 2024 Jul; 30(14):3036-3049. PubMed ID: 38630755
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular classification and biomarkers of outcome with immunotherapy in extensive-stage small-cell lung cancer: analyses of the CASPIAN phase 3 study.
    Xie M; Vuko M; Rodriguez-Canales J; Zimmermann J; Schick M; O'Brien C; Paz-Ares L; Goldman JW; Garassino MC; Gay CM; Heymach JV; Jiang H; Barrett JC; Stewart RA; Lai Z; Byers LA; Rudin CM; Shrestha Y
    Mol Cancer; 2024 May; 23(1):115. PubMed ID: 38811992
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression patterns and prognostic relevance of subtype-specific transcription factors in surgically resected small-cell lung cancer: an international multicenter study.
    Megyesfalvi Z; Barany N; Lantos A; Valko Z; Pipek O; Lang C; Schwendenwein A; Oberndorfer F; Paku S; Ferencz B; Dezso K; Fillinger J; Lohinai Z; Moldvay J; Galffy G; Szeitz B; Rezeli M; Rivard C; Hirsch FR; Brcic L; Popper H; Kern I; Kovacevic M; Skarda J; Mittak M; Marko-Varga G; Bogos K; Renyi-Vamos F; Hoda MA; Klikovits T; Hoetzenecker K; Schelch K; Laszlo V; Dome B
    J Pathol; 2022 Aug; 257(5):674-686. PubMed ID: 35489038
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular and Pathologic Characterization of YAP1-Expressing Small Cell Lung Cancer Cell Lines Leads to Reclassification as SMARCA4-Deficient Malignancies.
    Ng J; Cai L; Girard L; Prall OWJ; Rajan N; Khoo C; Batrouney A; Byrne DJ; Boyd DK; Kersbergen AJ; Christie M; Minna JD; Burr ML; Sutherland KD
    Clin Cancer Res; 2024 May; 30(9):1846-1858. PubMed ID: 38180245
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Concordance of ASCL1, NEUROD1 and POU2F3 transcription factor-based subtype assignment in paired tumour samples from small cell lung carcinoma.
    Denize T; Meador CB; Rider AB; Ganci ML; Barth JL; Kem M; Mino-Kenudson M; Hung YP
    Histopathology; 2023 Dec; 83(6):912-924. PubMed ID: 37644667
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Polymorphism in ASCL1 target gene DDC is associated with clinical outcomes of small cell lung cancer patients.
    Kim JH; Lee SY; Choi JE; Do SK; Lee JH; Hong MJ; Kang HG; Lee WK; Shin KM; Jeong JY; Choi SH; Lee YH; Seo H; Yoo SS; Lee J; Cha SI; Kim CH; Park JY
    Thorac Cancer; 2020 Jan; 11(1):19-28. PubMed ID: 31691490
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Application of Small Cell Lung Cancer Molecular Subtyping Markers to Small Cell Neuroendocrine Carcinoma of the Cervix: NEUROD1 as a Poor Prognostic Factor.
    Kim G; Kim M; Nam EJ; Lee JY; Park E
    Am J Surg Pathol; 2024 Mar; 48(3):364-372. PubMed ID: 37981832
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comprehensive analysis of transcription factor-based molecular subtypes and their correlation to clinical outcomes in small-cell lung cancer.
    Park S; Hong TH; Hwang S; Heeke S; Gay CM; Kim J; Jung HA; Sun JM; Ahn JS; Ahn MJ; Cho JH; Choi YS; Kim J; Shim YM; Kim HK; Byers LA; Heymach JV; Choi YL; Lee SH; Park K
    EBioMedicine; 2024 Apr; 102():105062. PubMed ID: 38492534
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BET Inhibitors Target the SCLC-N Subtype of Small-Cell Lung Cancer by Blocking NEUROD1 Transactivation.
    Chen H; Gesumaria L; Park YK; Oliver TG; Singer DS; Ge K; Schrump DS
    Mol Cancer Res; 2023 Feb; 21(2):91-101. PubMed ID: 36378541
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular Subtypes of Primary SCLC Tumors and Their Associations With Neuroendocrine and Therapeutic Markers.
    Qu S; Fetsch P; Thomas A; Pommier Y; Schrump DS; Miettinen MM; Chen H
    J Thorac Oncol; 2022 Jan; 17(1):141-153. PubMed ID: 34534680
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Construction of a prognostic model for extensive-stage small cell lung cancer patients undergoing immune therapy in northernmost China and prediction of treatment efficacy based on response status at different time points.
    Dang J; Xu G; Guo G; Zhang H; Shang L
    J Cancer Res Clin Oncol; 2024 May; 150(5):255. PubMed ID: 38750370
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical and molecular characterization of long-term survivors with extensive-stage small cell lung cancer treated with first-line atezolizumab plus carboplatin and etoposide.
    Liu SV; Mok TSK; Nabet BY; Mansfield AS; De Boer R; Losonczy G; Sugawara S; Dziadziuszko R; Krzakowski M; Smolin A; Hochmair MJ; Garassino MC; Gay CM; Heymach JV; Byers LA; Lam S; Cardona A; Morris S; Adler L; Shames DS; Reck M
    Lung Cancer; 2023 Dec; 186():107418. PubMed ID: 37931445
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SCLC Subtypes Defined by ASCL1, NEUROD1, POU2F3, and YAP1: A Comprehensive Immunohistochemical and Histopathologic Characterization.
    Baine MK; Hsieh MS; Lai WV; Egger JV; Jungbluth AA; Daneshbod Y; Beras A; Spencer R; Lopardo J; Bodd F; Montecalvo J; Sauter JL; Chang JC; Buonocore DJ; Travis WD; Sen T; Poirier JT; Rudin CM; Rekhtman N
    J Thorac Oncol; 2020 Dec; 15(12):1823-1835. PubMed ID: 33011388
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical utility of immunohistochemical subtyping in patients with small cell lung cancer.
    Chiang CL; Huang HC; Luo YH; Shen CI; Chao HS; Tseng YH; Chou TY; Schrump DS; Yeh YC; Chen YM
    Lung Cancer; 2024 Feb; 188():107473. PubMed ID: 38232600
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High mRNA expression of POU2F3 in small cell lung cancer cell lines predicts the effect of lurbinectedin.
    Matsui S; Haruki T; Oshima Y; Kidokoro Y; Sakabe T; Umekita Y; Nakamura H
    Thorac Cancer; 2022 Apr; 13(8):1184-1192. PubMed ID: 35278040
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Extensive-stage small-cell lung cancer in patients receiving atezolizumab plus carboplatin-etoposide: stratification of outcome based on a composite score that combines gene expression profiling and immune characterization of microenvironment.
    Tosi A; Lorenzi M; Del Bianco P; Roma A; Pavan A; Scapinello A; Resi MV; Bonanno L; Frega S; Calabrese F; Guarneri V; Rosato A; Pasello G
    J Immunother Cancer; 2024 Jul; 12(7):. PubMed ID: 38955418
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular features and evolutionary trajectory of ASCL1
    Zhang X; Wang H; Liu W; Xiao Z; Ma Z; Zhang Z; Gong W; Chen J; Liu Z
    Br J Cancer; 2023 Mar; 128(5):748-759. PubMed ID: 36517551
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of ASCL1, NEUROD1, and POU2F3 expression in surgically resected specimens, paired tissue microarrays, and lymph node metastases in small cell lung carcinoma.
    Handa T; Hayashi T; Ura A; Watanabe I; Takamochi K; Onagi H; Kishi M; Matsumoto N; Tajima K; Kishikawa S; Saito T; Takahashi K; Suzuki K; Yao T
    Histopathology; 2023 May; 82(6):860-869. PubMed ID: 36715573
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical characteristics and patient outcomes of molecular subtypes of small cell lung cancer (SCLC).
    Ding XL; Su YG; Yu L; Bai ZL; Bai XH; Chen XZ; Yang X; Zhao R; He JX; Wang YY
    World J Surg Oncol; 2022 Feb; 20(1):54. PubMed ID: 35220975
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessing treatment outcomes of chemoimmunotherapy in extensive-stage small cell lung cancer: an integrated clinical and radiomics approach.
    Zhao J; He Y; Yang X; Tian P; Zeng L; Huang K; Zhao J; Zhou J; Zhu Y; Wang Q; Chen M; Li W; Gao Y; Zhang Y; Xia Y
    J Immunother Cancer; 2023 Sep; 11(9):. PubMed ID: 37730276
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.